PMC7791350_01
Psoriatic and HS lesions of patient 1.. (
a-
e) Psoriatic and HS lesions of first patient before treatment with certolizumab pegol. (
f-
j) Psoriatic and HS lesions of first patient after treatment with certolizumab pegol.
f1000research-8-30681-g0000.jpg
PMC7791350_01_f1000research-8-30681-g0000.jpg
f1
Severity Index) score of 10.5 and 10% BSA (Body Surface Area) score. She, also, suffered from psoriatic arthritis with axial joint involvement (manifestations of hierolagonitis) over the previous 2 years and moderate HS of Hurley II stage disease on the axillae over the last year, with IHS4 (International Hidradenitis Suppurativa Severity Scoring System) score 10 ( Figure 1a, b, c, d, e). Except the clinical improvement, the DLQI score was impressively reduced to 2. ( Figure 1f-i).
PMC7791350_02
Psoriatic lesions of patient 2.. (
a-
d) Psoriatic lesions of second patient before treatment with brodalumab. (
e-
h) Psoriatic lesions of second patient after treatment with brodalumab.
f1000research-8-30681-g0001.jpg
PMC7791350_02_f1000research-8-30681-g0001.jpg
f2
The second patient, a 42-year-old Caucasian man, was referred to our hospital's dermatological department with multiple, itchy, scaly, red-gray psoriatic plaques covering almost all his body: scalp, arms, trunk, thighs ( Figure 2a-d) for the previous 6 months, over a history of 10 years psoriatic disease (recent PASI: 18.5, BSA: 45%). His psoriasis and psoriatic arthritis were highly improved at week 8 ( Figure 2 e-h), as was HS at week 16.